Bio-Imaging Technologies to Release First Quarter 2007 Financial Results and Host Conference Call on May 2, 2007.

NEWTOWN, Pa. -- Bio-Imaging Technologies, Inc. (NASDAQ: BITI) will release its financial results for the first quarter ended March 31, 2007 on Wednesday, May 2, 2007.

Management of Bio-Imaging Technologies, Inc. will host a conference call on the same day at 11 a.m. EDT to discuss the company's financial results and achievements. Those who wish to participate in the conference call may telephone [phone] from the U.S. or [phone] for international callers, passcode #8728298 approximately 15 minutes before the call. There will be a simultaneous webcast under "Investor Relations" at www.bioimaging.com. A digital replay will be available by telephone for two weeks and may be accessed by dialing [phone], from the U.S., or [phone], for international callers, passcode #8728298. The replay will also be available for two weeks under "Investor Relations" at www.bioimaging.com.

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands and its recent acquisition of Theralys SA in Lyon, France. Through its CapMed division, Bio-Imaging provides the Personal HealthKey[TM] technology and the Personal Health Record (PHR) software, allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at www.bioimaging.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.